

# S Munir Alam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7631882/publications.pdf>

Version: 2024-02-01

108  
papers

12,216  
citations

31976

53  
h-index

28297

105  
g-index

114  
all docs

114  
docs citations

114  
times ranked

9865  
citing authors

#	ARTICLE	IF	CITATIONS
1	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, eabj7125.	12.4	93
2	Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection. <i>MSphere</i> , 2022, 7, e0083921.	2.9	2
3	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. <i>Communications Biology</i> , 2022, 5, 271.	4.4	14
4	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. <i>Cell Reports</i> , 2022, 38, 110514.	6.4	23
5	B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates. <i>Cell Reports</i> , 2022, 39, 111021.	6.4	6
6	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , 2021, 594, 553-559.	27.8	199
7	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. <i>Cell</i> , 2021, 184, 2955-2972.e25.	28.9	57
8	Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials. <i>Frontiers in Big Data</i> , 2021, 4, 672460.	2.9	8
9	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021, 184, 4203-4219.e32.	28.9	228
10	Cold sensitivity of the SARS-CoV-2 spike ectodomain. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 128-131.	8.2	65
11	Vi-specific serological correlates of protection for typhoid fever. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	45
12	Magnitude, Specificity, and Avidity of Sporozoite-Specific Antibodies Associate With Protection Status and Distinguish Among RTS,S/AS01 Dose Regimens. <i>Open Forum Infectious Diseases</i> , 2021, 8, .	0.9	8
13	<i>Salmonella</i> Typhi Vi capsule prime-boost vaccination induces convergent and functional antibody responses. <i>Science Immunology</i> , 2021, 6, eabj1181.	11.9	7
14	Different adjuvanted pediatric HIV envelope vaccines induced distinct plasma antibody responses despite similar B cell receptor repertoires in infant rhesus macaques. <i>PLoS ONE</i> , 2021, 16, e0256885.	2.5	1
15	Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. <i>Journal of Virology</i> , 2020, 94, .	3.4	5
16	HIV Env-Specific IgG Antibodies Induced by Vaccination of Neonatal Rhesus Macaques Persist and Can Be Augmented by a Late Booster Immunization in Infancy. <i>MSphere</i> , 2020, 5, .	2.9	6
17	3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelopeâ€“specific plasma cells and humoral immunity in nonhuman primates. <i>Science Immunology</i> , 2020, 5, .	11.9	90
18	Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements. <i>Nature Communications</i> , 2020, 11, 520.	12.8	42

#	ARTICLE	IF	CITATIONS
19	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019, 10, 2898.	12.8	35
20	Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period. <i>Journal of Infectious Diseases</i> , 2019, 219, 1755-1765.	4.0	7
21	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008026.	4.7	56
22	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , 2019, 50, 677-691.e13.	14.3	77
23	Determinants of Tenascin-C and HIV-1 envelope binding and neutralization. <i>Mucosal Immunology</i> , 2019, 12, 1004-1012.	6.0	18
24	Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. <i>Nature Communications</i> , 2019, 10, 654.	12.8	34
25	IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model. <i>Frontiers in Immunology</i> , 2019, 10, 2582.	4.8	40
26	Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. <i>PLoS Pathogens</i> , 2019, 15, e1008165.	4.7	5
27	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. <i>Science</i> , 2019, 366, .	12.6	118
28	Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques. <i>Journal of Virology</i> , 2019, 93, .	3.4	18
29	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. <i>Journal of Virology</i> , 2018, 92, .	3.4	46
30	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018, 92, .	3.4	45
31	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. <i>Communications Biology</i> , 2018, 1, 134.	4.4	26
32	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. <i>Immunity</i> , 2018, 49, 1162-1174.e8.	14.3	61
33	Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with <i>Plasmodium falciparum</i> Circumsporozoite Protein Antigens. <i>Journal of Immunology</i> , 2018, 201, 1315-1326.	0.8	30
34	Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	3.4	39
35	Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. <i>Cell Host and Microbe</i> , 2018, 23, 759-765.e6.	11.0	98
36	Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. <i>Immunological Reviews</i> , 2017, 275, 145-160.	6.0	160

#	ARTICLE	IF	CITATIONS
37	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. <i>Journal of Immunology</i> , 2017, 198, 1047-1055.	0.8	7
38	Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. <i>Journal of Virology</i> , 2017, 91, .	3.4	73
39	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017, 2, .	11.9	119
40	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. <i>Cell Reports</i> , 2017, 18, 2175-2188.	6.4	69
41	Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. <i>Journal of Virology</i> , 2017, 91, .	3.4	5
42	Staged induction of HIV-1 glycanâ€“dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	212
43	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	81
44	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 859-868.	1.1	18
45	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. <i>Journal of Virology</i> , 2017, 91, .	3.4	23
46	Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. <i>Vaccine Journal</i> , 2017, 24, .	3.1	28
47	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017, 21, 3681-3690.	6.4	97
48	Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. <i>Blood Advances</i> , 2017, 1, 2329-2342.	5.2	90
49	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017, 8, 1732.	12.8	76
50	Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. <i>PLoS Pathogens</i> , 2016, 12, e1005817.	4.7	119
51	Conformationally selective RNA aptamers allosterically modulate the $\beta$ 2-adrenoceptor. <i>Nature Chemical Biology</i> , 2016, 12, 709-716.	8.0	65
52	HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. <i>Immunogenetics</i> , 2016, 68, 145-155.	2.4	18
53	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. <i>Journal of Virology</i> , 2016, 90, 5899-5914.	3.4	62
54	A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. <i>Cell Reports</i> , 2016, 15, 1505-1513.	6.4	43

#	ARTICLE	IF	CITATIONS
55	Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2016, 35, 217-226.	1.6	9
56	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. <i>Journal of Immunology</i> , 2016, 197, 4663-4673.	0.8	6
57	Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. <i>Science Translational Medicine</i> , 2016, 8, 336ra62.	12.4	86
58	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , 2016, 12, 196-207.	6.1	34
59	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	7.1	170
60	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016, 165, 449-463.	28.9	305
61	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. <i>Cell Reports</i> , 2016, 14, 43-54.	6.4	45
62	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. <i>PLoS ONE</i> , 2016, 11, e0157409.	2.5	44
63	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. <i>Viruses</i> , 2015, 7, 5443-5475.	3.3	26
64	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	4.7	145
65	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. <i>Journal of Virology</i> , 2015, 89, 6462-6480.	3.4	40
66	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	12.6	191
67	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. <i>EBioMedicine</i> , 2015, 2, 713-722.	6.1	13
68	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	11.0	66
69	Progress in HIV-1 vaccine development. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 3-10.	2.9	62
70	Estimating the Probability of Polyreactive Antibodies 4E10 and 2F5 Disabling a gp41 Trimer after T Cell-HIV Adhesion. <i>PLoS Computational Biology</i> , 2014, 10, e1003431.	3.2	3
71	TCR Affinity Associated with Functional Differences between Dominant and Subdominant SIV Epitope-Specific CD8+ T Cells in Mamu-A*01+ Rhesus Monkeys. <i>PLoS Pathogens</i> , 2014, 10, e1004069.	4.7	8
72	Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. <i>Frontiers in Immunology</i> , 2014, 5, 170.	4.8	104

#	ARTICLE	IF	CITATIONS
73	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. <i>Journal of Virology</i> , 2014, 88, 7715-7726.	3.4	169
74	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. <i>Immunity</i> , 2014, 41, 909-918.	14.3	65
75	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX <sup>A</sup> B/E in RV144 Vaccinees. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A36-A36.	1.1	1
76	IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria. <i>PLoS ONE</i> , 2014, 9, e90725.	2.5	37
77	Longitudinal Antibody Development in SHIVAD8 Infected Non-Human Primate. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A121-A121.	1.1	0
78	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. <i>Cell Host and Microbe</i> , 2014, 16, 304-313.	11.0	137
79	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. <i>Journal of Virology</i> , 2014, 88, 9406-9417.	3.4	16
80	HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria. <i>Cell Host and Microbe</i> , 2014, 16, 215-226.	11.0	105
81	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. <i>Cell</i> , 2014, 158, 481-491.	28.9	266
82	HIV-1 antibodies and vaccine antigen selectively interact with lipid domains. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2014, 1838, 2662-2669.	2.6	4
83	Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen. <i>Journal of Immunological Methods</i> , 2014, 404, 1-12.	1.4	35
84	Chemical Synthesis of Highly Congested gp120 V1V2 <i>N</i> -Glycopeptide Antigens for Potential HIV-1-Directed Vaccines. <i>Journal of the American Chemical Society</i> , 2013, 135, 13113-13120.	13.7	60
85	Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2013, 87, 4185-4201.	3.4	83
86	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013, 496, 469-476.	27.8	961
87	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	14.3	374
88	Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. <i>Journal of Virology</i> , 2013, 87, 1554-1568.	3.4	97
89	Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 18214-18219.	7.1	73
90	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. <i>New England Journal of Medicine</i> , 2012, 366, 1275-1286.	27.0	1,699

#	ARTICLE	IF	CITATIONS
91	Differential Reactivity of Germ Line Allelic Variants of a Broadly Neutralizing HIV-1 Antibody to a gp41 Fusion Intermediate Conformation. <i>Journal of Virology</i> , 2011, 85, 11725-11731.	3.4	56
92	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. <i>Journal of Virology</i> , 2011, 85, 9998-10009.	3.4	393
93	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. <i>Journal of Experimental Medicine</i> , 2011, 208, 2237-2249.	8.5	198
94	Programming the magnitude and persistence of antibody responses with innate immunity. <i>Nature</i> , 2011, 470, 543-547.	27.8	847
95	Rescue of HIV-1 Broad Neutralizing Antibody-Expressing B Cells in 2F5 VH $\Delta$ – VL Knockin Mice Reveals Multiple Tolerance Controls. <i>Journal of Immunology</i> , 2011, 187, 3785-3797.	0.8	97
96	Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting. <i>PLoS ONE</i> , 2011, 6, e23532.	2.5	137
97	Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41. <i>PLoS ONE</i> , 2011, 6, e27824.	2.5	75
98	Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 181-186.	7.1	172
99	Role of HIV membrane in neutralization by two broadly neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20234-20239.	7.1	225
100	Glycosylation Site-Specific Analysis of Clade C HIV-1 Envelope Proteins. <i>Journal of Proteome Research</i> , 2009, 8, 4231-4242.	3.7	87
101	Glycosylation Site-Specific Analysis of HIV Envelope Proteins (JR-FL and CON-S) Reveals Major Differences in Glycosylation Site Occupancy, Glycoform Profiles, and Antigenic Epitopes' Accessibility. <i>Journal of Proteome Research</i> , 2008, 7, 1660-1674.	3.7	133
102	The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes. <i>Journal of Immunology</i> , 2007, 178, 4424-4435.	0.8	230
103	Antibody polyspecificity and neutralization of HIV-1: A hypothesis. <i>Human Antibodies</i> , 2006, 14, 59-67.	1.5	142
104	Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies. <i>Science</i> , 2005, 308, 1906-1908.	12.6	704
105	An Inducible HIV Type 1 gp41 HR-2 Peptide-Binding Site on HIV Type 1 Envelope gp120. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 836-845.	1.1	42
106	Binding Kinetics of Superantigen with TCR and MHC Class II. , 2003, 214, 065-085.		1
107	T-cell receptor binding kinetics in T-cell development and activation. <i>Expert Reviews in Molecular Medicine</i> , 2001, 3, 1-17.	3.9	90
108	T Cell Receptor Binding Kinetics and Special Role of V $\beta$ in T Cell Development and Activation. <i>Immunologic Research</i> , 2000, 21, 225-232.	2.9	5